Literature DB >> 2113470

Heritable metabolic and dysplastic bone diseases.

M P Whyte1.   

Abstract

Endocrinologists may be challenged not only by the great diversity of rare heritable metabolic bone diseases, but also by an unusual array of genetically transmitted skeletal dysplasias. The striking impact that many such skeletal dysplasias have on bone leads physicians naturally to question whether there is a metabolic component that might respond to mineral or hormonal therapy. Indeed, overt derangements in mineral or hormonal therapy. Indeed, overt derangements in mineral homeostasis occur, and a few do respond to medical treatment. Accordingly, some skeletal dysplasias do "bridge the gap" with the disorders that are traditionally regarded as metabolic in origin. The skills of the endocrinologist may be called on for either group of patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113470

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  10 in total

1.  Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis.

Authors:  F Barvencik; F Timo Beil; M Gebauer; B Busse; T Koehne; S Seitz; J Zustin; P Pogoda; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2011-01-26       Impact factor: 4.507

2.  Hyperphosphatasia with massive osteoectasia: a 45-year follow-up.

Authors:  E F McCarthy; G H Sack
Journal:  Skeletal Radiol       Date:  2006-08-17       Impact factor: 2.199

3.  Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13.

Authors:  K Janssens; R Gershoni-Baruch; E Van Hul; R Brik; N Guañabens; N Migone; L A Verbruggen; S H Ralston; M Bonduelle; L Van Maldergem; F Vanhoenacker; W Van Hul
Journal:  J Med Genet       Date:  2000-04       Impact factor: 6.318

4.  Clinical, radiographic and biochemical characteristics of adult hypophosphatasia.

Authors:  T Schmidt; H Mussawy; T Rolvien; T Hawellek; J Hubert; W Rüther; M Amling; F Barvencik
Journal:  Osteoporos Int       Date:  2017-05-25       Impact factor: 4.507

5.  Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia.

Authors:  H J Girschick; P Schneider; I Haubitz; O Hiort; H Collmann; M Beer; Y S Shin; H W Seyberth
Journal:  Orphanet J Rare Dis       Date:  2006-06-28       Impact factor: 4.123

6.  Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy.

Authors:  Hermann J Girschick; Etienne Mornet; Meinrad Beer; Monika Warmuth-Metz; Peter Schneider
Journal:  BMC Pediatr       Date:  2007-01-23       Impact factor: 2.125

7.  Total femur arthroplasty for revision hip failure in osteogenesis imperfecta: limits of biology.

Authors:  Pablo Sanz-Ruiz; Manuel Villanueva-Martinez; Jose Antonio Calvo-Haro; Esther Carbó-Laso; Javier Vaquero-Martín
Journal:  Arthroplast Today       Date:  2017-03-06

8.  Custom hemiarthroplasties for retention of existing hardware associated with osteogenesis imperfecta.

Authors:  Kevin Nishida; Daniel Choi; Mathias Bostrom
Journal:  Arthroplast Today       Date:  2017-03-03

9.  MYOSITIS OSSIFICANS PROGRESSIVA: CASE REPORT.

Authors:  Frederico Barra de Moraes; Alano Ribeiro de Queiroz Filho; Leonardo Jorge da Silva; Válney Luiz da Rocha; Nayara Portilho Araújo; Ernesto Quaresma Mendonça; Érica Paiva de Almeida
Journal:  Rev Bras Ortop       Date:  2015-12-06

10.  Genetic engineering a large animal model of human hypophosphatasia in sheep.

Authors:  Diarra K Williams; Carlos Pinzón; Shannon Huggins; Jane H Pryor; Alyssa Falck; Forrest Herman; James Oldeschulte; Michael B Chavez; Brian L Foster; Sarah H White; Mark E Westhusin; Larry J Suva; Charles R Long; Dana Gaddy
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.